Eli Lilly reported strong earnings for the fourth quarter of 2023, with revenue increasing by 8% and beating analysts’ expectations. The pharmaceutical company also announced positive results from clinical trials for several of its key drugs, leading to an optimistic outlook for future growth. However, the stock price did not see a significant increase following the earnings report.

$5 / month
ShortyPRO Monthly
Monthly ShortyPRO subscription:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World
+ All future updates and features!
Free trial
ShortyPRO Trial
ShortyPRO experience for two weeks:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World